Delortan Actions

How do you administer this medicine?
sponsored

Actions of Delortan in details

The action of the drug on the human body is called Pharmacodynamics in Medical terminology. To produce its effect and to change the pathological process that is happening the body and to reduce the symptom or cure the disease, the medicine has to function in a specific way. The changes it does to the body at cellular level gives the desired result of treating a disease. Drugs act by stimulating or inhibiting a receptor or an enzyme or a protein most of the times. Medications are produced in such a way that the ingredients target the specific site and bring about chemical changes in the body that can stop or reverse the chemical reaction which is causing the disease.
sponsored

Pharmacology: Delortan is the orally active, nonsedating, active metabolite of loratadine, with a sustained duration of action that allows once-daily dosing in clinical use.

Mechanism of Action: Delortan is a new, selective peripheral histamine H1-receptor antagonist with more potent antiallergenic properties than loratadine itself. It also has anti-inflammatory activity. Delortan acts by inhibiting the release of pro-inflammatory mediators from human mast cells/basophils.

Delortan was more potent than loratadine with respect to in vivo inhibition of histamine-induced wheal and flare. It does not readily penetrate the central nervous system.

Delortan demonstrates H1-receptor specificity including 15- to 50-fold lower affinity for muscarinic receptors compared with H1-receptors.

Clinical studies have demonstrated that Delortan has a lack of clinically significant cardiovascular toxicity, and unlike most other antihistamines, has decongestant effects.

Pharmacokinetics: After oral administration, Delortan is rapidly and almost completely absorbed. Peak plasma concentrations are reached within about 3 hrs; the terminal elimination half-life of Delortan is averaged 24-27 hrs, indicating that Delortan is suitable for once-daily administration. The pharmacokinetics of Delortan is linear and exhibits dose proportionality. With daily administration of 5 mg of Delortan, steady-state serum concentrations are achieved within 7 days.

Delortan is rapidly metabolised by hydroxylation to 3-hydroxydesloratadine and excreted mainly in the urine.

Because the bioavailability and absorption of Delortan are not significantly affected by food, Delortan may be administered with or without meals.

Pharmacokinetic studies with Delortan in the elderly and in patients with renal dysfunction are not yet available. The available data for loratadine indicate that the elimination half-life of Delortan may be increased in patients with chronic renal failure. However, dosage reduction in mild to moderate renal impairment is probably not necessary.

Limited pharmacokinetic data suggest that Delortan 5 mg daily is likely to be safe in patients with hepatic dysfunction.

How should I take Delortan?

Take Delortan exactly as prescribed by your doctor. Do not take in larger or smaller amounts or for longer than recommended. Follow the directions on your prescription label.

Delortan is usually taken once per day. Follow your doctor's instructions.

Do not crush, chew, or break the regular Delortan tablet. Swallow the pill whole.

Measure the liquid form of Delortan with a special dose-measuring spoon or cup, not a regular table spoon. If you do not have a dose-measuring device, ask your pharmacist for one.

To take Delortan orally disintegrating tablet (Delortan RediTabs):

Call your doctor if your symptoms do not improve.

Store Delortan at room temperature away from moisture and heat.

Delortan administration

Administration of drug is important to know because the drug absorption and action varies depending on the route and time of administration of the drug. A medicine is prescribed before meals or after meals or along with meals. The specific timing of the drug intake about food is to increase its absorption and thus its efficacy. Few work well when taken in empty stomach and few medications need to be taken 1 or 2 hrs after the meal. A drug can be in the form of a tablet, a capsule which is the oral route of administration and the same can be in IV form which is used in specific cases. Other forms of drug administration can be a suppository in anal route or an inhalation route.
sponsored

Take exactly as prescribed by your doctor. Do not take in larger or smaller amounts or for longer than recommended. Follow the directions on your prescription label.

Delortan is usually taken once per day. Follow your doctor's instructions.

Do not crush, chew, or break the regular Delortan tablet. Swallow the pill whole.

Measure the liquid form of Delortan with a special dose-measuring spoon or cup, not a regular table spoon. If you do not have a dose-measuring device, ask your pharmacist for one.

To take Delortan orally disintegrating tablet (Delortan RediTabs):

Store at room temperature away from moisture and heat.

Call your doctor if your symptoms do not improve.

Delortan pharmacology

Pharmacokinetics of a drug can be defined as what body does to the drug after it is taken. The therapeutic result of the medicine depends upon the Pharmacokinetics of the drug. It deals with the time taken for the drug to be absorbed, metabolized, the process and chemical reactions involved in metabolism and about the excretion of the drug. All these factors are essential to deciding on the efficacy of the drug. Based on these pharmacokinetic principles, the ingredients, the Pharmaceutical company decides dose and route of administration. The concentration of the drug at the site of action which is proportional to therapeutic result inside the body depends on various pharmacokinetic reactions that occur in the body.
sponsored

Mechanism of Action

Delortan is a long-acting tricyclic histamine antagonist with selective H1-receptor histamine antagonist activity. Receptor binding data indicates that at a concentration of 2–3 ng/mL (7 nanomolar), Delortan shows significant interaction with the human histamine H1-receptor. Delortan inhibited histamine release from human mast cells in vitro. Results of a radiolabeled tissue distribution study in rats and a radioligand H1-receptor binding study in guinea pigs showed that Delortan did not readily cross the blood brain barrier. The clinical significance of this finding is unknown.

Pharmacodynamics

Wheal and Flare: Human histamine skin wheal studies following single and repeated 5-mg doses of Delortan have shown that the drug exhibits an antihistaminic effect by 1 hour; this activity may persist for as long as 24 hours. There was no evidence of histamine-induced skin wheal tachyphylaxis within the Delortan 5-mg group over the 28-day treatment period. The clinical relevance of histamine wheal skin testing is unknown.

Effects on QTc: Single daily doses of 45 mg were given to normal male and female volunteers for 10 days. All ECGs obtained in this study were manually read in a blinded fashion by a cardiologist. In Delortan-treated subjects, there was an increase in mean heart rate of 9.2 bpm relative to placebo. The QT interval was corrected for heart rate (QTc) by both the Bazett and Fridericia methods. Using the QTc (Bazett) there was a mean increase of 8.1 msec in Delortan-treated subjects relative to placebo. Using QTc (Fridericia) there was a mean increase of 0.4 msec in Delortan-treated subjects relative to placebo. No clinically relevant adverse events were reported.

Pharmacokinetics

Absorption

Following oral administration of a Delortan 5-mg tablet once daily for 10 days to normal healthy volunteers, the mean time to maximum plasma concentrations (Tmax) occurred at approximately 3 hours post dose and mean steady state peak plasma concentrations (Cmax) and AUC of 4 ng/mL and 56.9 ng∙hr/mL were observed, respectively. Neither food nor grapefruit juice had an effect on the bioavailability (Cmax and AUC) of Delortan.

The pharmacokinetic profile of Delortan

Oral Solution was evaluated in a three-way crossover study in 30 adult volunteers. A single dose of 10 mL of Delortan

Oral Solution containing 5 mg of Delortan was bioequivalent to a single dose of 5-mg Delortan Tablet. Food had no effect on the bioavailability (AUC and Cmax) of Delortan

Oral Solution.

The pharmacokinetic profile of Delortan RediTabs Tablets was evaluated in a three-way crossover study in 24 adult volunteers. A single Delortan RediTabs Tablet containing 5 mg of Delortan was bioequivalent to a single 5-mg Delortan RediTabs Tablet (original formulation) for both Delortan and 3-hydroxydesloratadine. Food and water had no effect on the bioavailability (AUC and Cmax) of Delortan RediTabs Tablets.

Distribution

Delortan and 3-hydroxydesloratadine are approximately 82% to 87% and 85% to 89% bound to plasma proteins, respectively. Protein binding of Delortan and 3-hydroxydesloratadine was unaltered in subjects with impaired renal function.

Metabolism

Delortan (a major metabolite of loratadine) is extensively metabolized to 3-hydroxydesloratadine, an active metabolite, which is subsequently glucuronidated. The enzyme(s) responsible for the formation of 3-hydroxydesloratadine have not been identified. Data from clinical trials indicate that a subset of the general population has a decreased ability to form 3-hydroxydesloratadine, and are poor metabolizers of Delortan. In pharmacokinetic studies (n=3748), approximately 6% of subjects were poor metabolizers of Delortan (defined as a subject with an AUC ratio of 3-hydroxydesloratadine to Delortan less than 0.1, or a subject with a Delortan half-life exceeding 50 hours). These pharmacokinetic studies included subjects between the ages of 2 and 70 years, including 977 subjects aged 2 to 5 years, 1575 subjects aged 6 to 11 years, and 1196 subjects aged 12 to 70 years. There was no difference in the prevalence of poor metabolizers across age groups. The frequency of poor metabolizers was higher in Blacks (17%, n=988) as compared to Caucasians (2%, n=1,462) and Hispanics (2%, n=1,063). The median exposure (AUC) to Delortan in the poor metabolizers was approximately 6-fold greater than in the subjects who are not poor metabolizers. Subjects who are poor metabolizers of Delortan cannot be prospectively identified and will be exposed to higher levels of Delortan following dosing with the recommended dose of Delortan. In multidose clinical safety studies, where metabolizer status was identified, a total of 94 poor metabolizers and 123 normal metabolizers were enrolled and treated with Delortan

Oral Solution for 15–35 days. In these studies, no overall differences in safety were observed between poor metabolizers and normal metabolizers. Although not seen in these studies, an increased risk of exposure-related adverse events in patients who are poor metabolizers cannot be ruled out.

Elimination

The mean plasma elimination half-life of Delortan was approximately 27 hours. Cmax and AUC values increased in a dose proportional manner following single oral doses between 5 and 20 mg. The degree of accumulation after 14 days of dosing was consistent with the half-life and dosing frequency. A human mass balance study documented a recovery of approximately 87% of the 14C-Delortan dose, which was equally distributed in urine and feces as metabolic products. Analysis of plasma 3-hydroxydesloratadine showed similar Tmax and half-life values compared to Delortan.

Special Populations

Geriatric Subjects: In older subjects (≥65 years old; n=17) following multiple-dose administration of Delortan Tablets, the mean Cmax and AUC values for Delortan were 20% greater than in younger subjects (<65 years old). The oral total body clearance (CL/F) when normalized for body weight was similar between the two age groups. The mean plasma elimination half-life of Delortan was 33.7 hr in subjects ≥65 years old. The pharmacokinetics for 3-hydroxydesloratadine appeared unchanged in older versus younger subjects. These age-related differences are unlikely to be clinically relevant and no dosage adjustment is recommended in elderly subjects.

Pediatric Subjects: In subjects 6 to 11 years old, a single dose of 5 mL of Delortan

Oral Solution containing 2.5 mg of Delortan, resulted in Delortan plasma concentrations similar to those achieved in adults administered a single 5-mg Delortan Tablet. In subjects 2 to 5 years old, a single dose of 2.5 mL of Delortan

Oral Solution containing 1.25 mg of Delortan, resulted in Delortan plasma concentrations similar to those achieved in adults administered a single 5-mg Delortan Tablet. However, the Cmax and AUC of the metabolite (3-hydroxydesloratadine) were 1.27 and 1.61 times higher for the 5-mg dose of

Oral Solution administered in adults compared to the Cmax and AUC obtained in children 2 to 11 years of age receiving 1.25–2.5 mg of Delortan

Oral Solution.

A single dose of either 2.5 mL or 1.25 mL of Delortan

Oral Solution containing 1.25 mg or 0.625 mg, respectively, of Delortan was administered to subjects 6 to 11 months of age and 12 to 23 months of age. The results of a population pharmacokinetic analysis indicated that a dose of 1 mg for subjects aged 6 to 11 months and 1.25 mg for subjects 12 to 23 months of age is required to obtain Delortan plasma concentrations similar to those achieved in adults administered a single 5-mg dose of Delortan

Oral Solution.

The Delortan RediTabs 2.5-mg tablet has not been evaluated in pediatric patients. Bioequivalence of the Delortan RediTabs Tablet and the original Delortan RediTabs Tablets was established in adults. In conjunction with the dose-finding studies in pediatrics described, the pharmacokinetic data for Delortan RediTabs Tablets supports the use of the 2.5-mg dose strength in pediatric patients 6 to 11 years of age.

Renally Impaired: Delortan pharmacokinetics following a single dose of 7.5 mg were characterized in patients with mild (n=7; creatinine clearance 51–69 mL/min/1.73 m2), moderate (n=6; creatinine clearance 34–43 mL/min/1.73 m2), and severe (n=6; creatinine clearance 5–29 mL/min/1.73 m2) renal impairment or hemodialysis dependent (n=6) patients. In patients with mild and moderate renal impairment, median Cmax and AUC values increased by approximately 1.2- and 1.9-fold, respectively, relative to subjects with normal renal function. In patients with severe renal impairment or who were hemodialysis dependent, Cmax and AUC values increased by approximately 1.7- and 2.5-fold, respectively. Minimal changes in 3-hydroxydesloratadine concentrations were observed. Delortan and 3-hydroxydesloratadine were poorly removed by hemodialysis. Plasma protein binding of Delortan and 3-hydroxydesloratadine was unaltered by renal impairment. Dosage adjustment for patients with renal impairment is recommended.

Hepatically Impaired: Delortan pharmacokinetics were characterized following a single oral dose in patients with mild (n=4), moderate (n=4), and severe (n=4) hepatic impairment as defined by the Child-Pugh classification of hepatic function and 8 subjects with normal hepatic function. Patients with hepatic impairment, regardless of severity, had approximately a 2.4-fold increase in AUC as compared with normal subjects. The apparent oral clearance of Delortan in patients with mild, moderate, and severe hepatic impairment was 37%, 36%, and 28% of that in normal subjects, respectively. An increase in the mean elimination half-life of Delortan in patients with hepatic impairment was observed. For 3-hydroxydesloratadine, the mean Cmax and AUC values for patients with hepatic impairment were not statistically significantly different from subjects with normal hepatic function. Dosage adjustment for patients with hepatic impairment is recommended.

Gender: Female subjects treated for 14 days with Delortan Tablets had 10% and 3% higher Delortan Cmax and AUC values, respectively, compared with male subjects. The 3-hydroxydesloratadine Cmax and AUC values were also increased by 45% and 48%, respectively, in females compared with males. However, these apparent differences are not likely to be clinically relevant and therefore no dosage adjustment is recommended.

Race: Following 14 days of treatment with Delortan Tablets, the Cmax and AUC values for Delortan were 18% and 32% higher, respectively, in Blacks compared with Caucasians. For 3-hydroxydesloratadine there was a corresponding 10% reduction in Cmax and AUC values in Blacks compared to Caucasians. These differences are not likely to be clinically relevant and therefore no dose adjustment is recommended.

Drug Interactions: In two controlled crossover clinical pharmacology studies in healthy male (n=12 in each study) and female (n=12 in each study) volunteers, Delortan 7.5 mg (1.5 times the daily dose) once daily was coadministered with erythromycin 500 mg every 8 hours or ketoconazole 200 mg every 12 hours for 10 days. In three separate controlled, parallel group clinical pharmacology studies, Delortan at the clinical dose of 5 mg has been coadministered with azithromycin 500 mg followed by 250 mg once daily for 4 days (n=18) or with fluoxetine 20 mg once daily for 7 days after a 23-day pretreatment period with fluoxetine (n=18) or with cimetidine 600 mg every 12 hours for 14 days (n=18) under steady-state conditions to normal healthy male and female volunteers. Although increased plasma concentrations (Cmax and AUC0-24 hrs) of Delortan and 3-hydroxydesloratadine were observed, there were no clinically relevant changes in the safety profile of Delortan, as assessed by electrocardiographic parameters (including the corrected QT interval), clinical laboratory tests, vital signs, and adverse events.

Table 2: Changes in Delortan and 3-Hydroxydesloratadine Pharmacokinetics in Healthy Male and Female Volunteers
Delortan 3-Hydroxydesloratadine
Cmax AUC0-24 hrs Cmax AUC0-24 hrs
Erythromycin

(500 mg Q8h)

+ 24% + 14% + 43% + 40%

Ketoconazole

(200 mg Q12h)

+ 45%

+ 39%

+ 43%

+ 72%

Azithromycin

(500 mg day 1,

250 mg QD x 4 days)

+ 15%

+ 5%

+ 15%

+ 4%

Fluoxetine

(20 mg QD)

+ 15%

+ 0%

+ 17%

+ 13%

Cimetidine

(600 mg Q12h)

+ 12%

+ 19%

- 11%

- 3%



References

  1. DailyMed. "DESLORATADINE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
  2. NCIt. "Desloratadine: NCI Thesaurus (NCIt) provides reference terminology for many systems. It covers vocabulary for clinical care, translational and basic research, and public information and administrative activities.". https://ncit.nci.nih.gov/ncitbrowser... (accessed September 17, 2018).
  3. EPA DSStox. "Desloratadine: DSSTox provides a high quality public chemistry resource for supporting improved predictive toxicology.". https://comptox.epa.gov/dashboard/ds... (accessed September 17, 2018).

Reviews

The results of a survey conducted on ndrugs.com for Delortan are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Delortan. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.

User reports

Consumer reported administration

No survey data has been collected yet


Consumer reviews


There are no reviews yet. Be the first to write one!


Your name: 
Email: 
Spam protection:  < Type 30 here

Information checked by Dr. Sachin Kumar, MD Pharmacology

| Privacy Policy
This site does not supply any medicines. It contains prices for information purposes only.
© 2003 - 2022 ndrugs.com All Rights Reserved